Background No studies to date have employed the EuroQoL EQ-5D questionnaire to assess health-related quality of life (HRQoL) in patients with pemphigus. Objectives To evaluate the HRQoL of patients with pemphigus by the EQ-5D and to analyse the convergent and known-groups validity of the EQ-5D in this patient population. Methods Between 2014 and 2017, a multicentre cross-sectional study was carried out. Outcome measures included the five-level EQ-5D (EQ-5D-5L), Dermatology Life Quality Index (DLQI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and an average pain intensity visual analogue scale (VAS) for the past 3 months. Results In total, 109 consecutive patients with pemphigus participated in the study (mean age 57 years; 64% women). Among the EQ-5D dimensions, the most problems were reported regarding pain/discomfort (50%), mobility (43%) and anxiety/depression (43%). No significant difference was found in mean EQ-5D index scores between patients with pemphigus vulgaris and those with pemphigus foliaceus (0Á81 vs. 0Á86, P = 0Á14). The mean EQ-5D index scores of patients with limited, moderate, significant and extreme pemphigus were 0Á88, 0Á82, 0Á72 and 0Á67, respectively (P = 0Á001). The number of comorbidities was associated with greater impairment in EQ-5D index scores (P < 0Á001). DLQI (r s = À0Á62, P < 0Á001) and the average pain intensity VAS (r s = À0Á59, P < 0Á001) more strongly correlated with the EQ-5D index scores than did ABSIS (r s = À0Á40, P < 0Á001). Conclusions This is the first study employing the EQ-5D questionnaire in pemphigus. The EQ-5D is a valid measure of HRQoL in patients with pemphigus that can be useful both in clinical practice and in economic evaluations to assess the health gains associated with new effective treatments.
• The EQ-5D is a valid instrument for the evaluation of health-related quality of life in pemphigus vulgaris and pemphigus foliaceus.
• Pain intensity, mucocutaneous involvement and comorbidities are important predictors of quality of life.
What are the clinical implications of this work?
• The EQ-5D might help physicians to understand better the health loss from pemphigus.
Pemphigus is a group of mucocutaneous autoimmune blistering diseases caused by autoantibodies against cell-surface proteins on keratinocytes. The major subtypes include pemphigus vulgaris (PV), pemphigus foliaceus (PF) and a less frequent form, IgA pemphigus. 1 PV accounts for approximately 70 -90% of all cases, with an annual incidence rate of 0Á76-32 per million. 2, 3 The usual age of onset is 50-60 years, and the female-to-male ratio ranges between 1Á1 and 2Á3 in Europe and Asia, although it is much higher (4Á0-4Á1) in Africa. 4 The clinical manifestation of PV is characterized by the formation of blisters that easily rupture leaving erosions on the skin and/or mucosa. 5 Although it may develop in any location, the most commonly affected sites are the scalp, face, neck, trunk, groin and oropharyngeal mucosa. 6 In contrast, patients with PF rarely develop mucosal involvement. Lesions in pemphigus may be highly painful, show no tendency to heal spontaneously, and are susceptible to superinfection. According to current guidelines, systemic corticosteroid therapy is regarded as the first-line treatment in pemphigus. [7] [8] [9] An important milestone of 2017 was rituximab combined with short-term prednisone being granted approval as a first-line treatment for PV by the U.S. Food and Drug Administration. 10 The detrimental impact of pemphigus and treatmentrelated side-effects on health-related quality of life (HRQoL) have been reported in the literature. [11] [12] [13] However, so far no health utility values have been measured in patients with pemphigus. Health utilities are preference-based HRQoL values that are needed to calculate quality-adjusted life-years in cost-effectiveness analyses of treatments. Of the commonly used generic instruments, the EuroQoL 5-Dimension (EQ-5D) questionnaire is advocated as a validated, self-reporting tool to derive utility scores. 14 Given the general character of the EQ-5D, it allows comparisons across a broad range of disease areas. The EQ-5D has demonstrated good validity and responsiveness in a number of dermatological conditions, including psoriasis, atopic dermatitis, hidradenitis suppurativa and acne. [15] [16] [17] However, no studies to date have employed the EQ-5D questionnaire in patients with pemphigus. Therefore, the objectives of our study were (i) to evaluate HRQoL in patients with pemphigus using the EQ-5D, (ii) to compare the burden of PV and PF with that of psoriasis measured by the EQ-5D and (iii) to analyse the convergent and known-groups validity of the EQ-5D in patients with pemphigus.
Patients and methods

Study design and patients
Between December 2014 and June 2017, a cross-sectional study was conducted in four academic dermatology departments in Hungary. Consecutive patients over 18 years of age diagnosed with any form of pemphigus were enrolled after an informed consent form was read and signed. Permission for conducting the study was granted by the national scientific and ethical committee (reference no. ETT-TUKEB 27416-3/ 2016/EKU). The questionnaire consisted of two sections. The patients' section included questions regarding demographic data, comorbidities and HRQoL. The physicians' section contained questions referring to disease characteristics, medical history, disease severity and treatments applied.
Outcome measures
Five-level EQ-5D
The validated Hungarian version of the five-level EQ-5D (EQ-5D-5L) questionnaire was used in the study. EQ-5D-5L is a generic, self-reported, preference-based measure of health that consists of a five-item descriptive system and a visual analogue scale (EQ VAS). 18 The five dimensions of health ask about mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has five response levels (1, no problems; 2, slight problems; 3, moderate problems; 4, severe problems; 5, extreme problems/unable), and the different combinations of answers define 5 5 = 3125 distinct health states. 19, 20 Each health state can be assigned a utility value (i.e. EQ-5D-5L index score) obtained from population studies reflecting the societal values. In the absence of a national value set in Hungary, the 5L value set for England developed by Devlin et al. was applied in this study to derive utility values, whereby utilities range between À0Á285 and 1. 21 EQ VAS is a 20-cm, vertical VAS with end points of 0 ('the worst health you can imagine') and 100 ('the best health you can imagine'). It provides a self-rating of patients' current health status.
Dermatology Life Quality Index
The validated Hungarian version of the Dermatology Life Quality Index (DLQI) was administered to patients. 22 We decided to use the DLQI as it is the most frequently employed tool for measuring dermatology-specific HRQoL in patients with pemphigus. 23, 24 It has been successfully used in crosssectional and case-control studies, as well as in the Ritux 3 clinical trial for first-line rituximab in pemphigus. [25] [26] [27] [28] [29] [30] The 10-item questionnaire covers the commonly mentioned aspects of life affected by skin disease: symptoms and feelings, daily activities, leisure, school and work, personal relationships and treatments. The DLQI has a possible scoring range of 0-30, with 30 corresponding to the worst and 0 corresponding to the best score.
Autoimmune Bullous Skin Disorder Intensity Score
The Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) is a validated disease severity scale for pemphigus. [31] [32] [33] The ABSIS score ranges between 0 and 206, with 150 points for skin involvement, 11 points for oral involvement and 45 points for subjective discomfort. As HRQoL is based on subjective perceptions of the patients, we considered the ABSIS with its subjective component to be particularly useful to test the convergent validity of the EQ-5D. Of note, as there is no relevant difference in diet between Western Europe and Hungary with respect to the food item list of ABSIS, the foods were kept exactly the same as in the English-language version. 
Global and pain assessments
To assess disease severity the Physician's Global Assessment (PGA) VAS and Patient's Global Assessment (PtGA) VAS were administered, both providing a range of scores from 0 to 100, where 0 indicated 'not severe at all' and 100 represented 'very severe'. The average and worst pemphigus-related pain intensities experienced by the patients in the past 3 months were recorded on a 10-cm, horizontal VAS with end points of 'no pain at all' (score 0) and 'pain as bad as it could be' (score 100). 35 
Statistical analyses
Demographic and clinical characteristics were reported as proportions for categorical variables, and means with SDs and medians with interquartile ranges for continuous variables. The nonparametric Mann-Whitney U-test and the KruskalWallis H-test were used to compare patient-and physicianbased outcome scores in subgroups of patients. Analysis of the relationship between continuous variables was accomplished by calculating Spearman's correlation coefficients (very weak correlation: r s < 0Á2, weak 0Á20-0Á4, moderate 0Á4-0Á6 and strong 0Á6-1). The EQ-5D-5L and EQ VAS results were compared with responses from a group of Hungarian patients with psoriasis obtained in a previous study by our research group (n = 238, mean age 47Á4 AE 15Á2 years, proportion with moderate-to-severe psoriasis 81%). 36 For all the statistical tests a two-sided P-value < 0Á05 was considered statistically significant. All statistical analyses were performed using SPSS 22Á0 (IBM, Armonk, NY, U.S.A.).
Results
Patient characteristics
In total, 109 patients with pemphigus participated in the study. Their mean age was 57Á2 AE 14Á8 years (range 19-93) and 64Á2% were female (Table S1 ; see Supporting Information). Nearly 80% completed at least a high school education. The proportion of patients over the retirement age was 30Á3%. The mean disease duration was 3Á8 years. The most frequently represented subtype was PV (n = 81), while 27 patients presented with PF and one patient had IgA pemphigus. The majority of patients had limited (45Á9%) or moderate (30Á3%) pemphigus at the time of the survey. The most commonly used treatments were systemic corticosteroids (70Á6%), azathioprine (42Á2%) and cyclophosphamide (10Á1%) (combinations occurred).
Disease severity and health-related quality-of-life scores
Overall, 50%, 43%, 43%, 42% and 19% of the patients with pemphigus reported problems in the pain/discomfort, mobility, anxiety/depression, usual activities and self-care dimensions of the EQ-5D-5L descriptive system, respectively. Sixty different EQ-5D-5L health states occurred among the patients. The best health state (11111) was indicated by 31 patients (28Á7%); thus, a substantial ceiling effect of the EQ-5D-5L descriptive system was detected. No negative EQ-5D-5L index scores were observed (i.e. health states being worse than death). The mean EQ-5D-5L index and EQ VAS scores were 0Á82 AE 0Á21 and 68Á0 AE 22Á3, respectively (Table S2 ; see Supporting Information). The mean DLQI score was 5Á4 AE 6Á9, with the most problems reported regarding sore, itchy or painful skin (48%), embarrassment (48%) and clothing (36%). Overall, 40 patients (37Á4%) had a DLQI total score of zero. The mean ABSIS score for the sample was 11Á7 AE 17Á3. Mean scores on the PGA VAS were significantly lower than on the PtGA VAS (26Á9 AE 27Á4 vs. 46Á0 AE 35Á5; P < 0Á001). The mean worst pain intensity VAS scores were significantly higher than the mean pain intensity scores (33Á6 AE 37Á6 vs. 21Á4 AE 30Á6; P < 0Á001).
Comparison of patients with pemphigus vulgaris and pemphigus foliaceus
ABSIS scores showed a trend towards a higher severity score in PV (mean 13Á4 AE 18Á1) than in PF (mean 7Á1 AE 14Á5) (Table S2) . Patients affected by PV tended to have worse scores both in EQ-5D-5L index and EQ VAS. However, patients with PF experienced greater HRQoL impairment as measured with the DLQI. Patients with PV indicated significantly higher scores on worst pain intensity VAS compared with patients with PF (P < 0Á05).
EQ-5D-5L and EQ VAS results of patients with pemphigus vulgaris and pemphigus foliaceus in comparison with a previous study in psoriasis
A greater proportion of patients with PV indicated problems in all five dimensions of the EQ-5D-5L than patients with PF, especially concerning usual activities and mobility ( Fig. 1) . In all dimensions, patients with PV reported approximately equal or more problems than patients with psoriasis, while patients with PF experienced nearly equal or fewer problems than patients with psoriasis. When patients with PV and patients with psoriasis were compared, the most pronounced difference was observed in usual activities (51% vs. 32% reported at least slight problems, and 11% vs. 3% reported severe or extreme problems). The EQ-5D-5L index (0Á84) and EQ VAS scores (72Á5) of patients with psoriasis were very similar to those of patients with PV and PF (P > 0Á05).
Fig 1.
Distribution of responses to the five dimensions of the EQ-5D-5L in patients with pemphigus vulgaris and pemphigus foliaceus compared with patients with psoriasis. The psoriasis data are for Hungary (n = 238, mean age 47Á4 AE 15Á2 years, 81% with moderate-to-severe psoriasis), derived from Po or et al.
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Convergent validity EQ-5D-5L index scores demonstrated a strong correlation with DLQI and EQ VAS scores, a moderate-to-strong correlation with average pain intensity VAS and a moderate correlation with ABSIS, PGA VAS, PtGA VAS and worst pain intensity VAS scores (P < 0Á001) (Table S3 ; see Supporting Information). In contrast, EQ VAS moderately correlated with the DLQI and the scores on pain intensity scales (P < 0Á001). There was a weak, insignificant correlation between the EQ VAS and ABSIS scores. PGA VAS highly correlated with both the DLQI and ABSIS (P < 0Á001). A weak negative correlation was found between age and both the EQ-5D-5L index score (P < 0Á01) and the EQ VAS (P < 0Á05).
Known-groups validity
There was no statistically significant difference in EQ-5D-5L index scores between female and male patients (Table S4 ; see Supporting Information). The mean EQ-5D-5L index scores of patients with limited, moderate, severe and extreme disease were 0Á88 AE 0Á18, 0Á82 AE 0Á21, 0Á72 AE 0Á23 and 0Á67 AE 0Á24, respectively (P = 0Á001). Similarly, it was possible to detect a significant difference across patients with PV with no lesions, mucocutaneous lesions, skin involvement only and mucosal lesions only (P = 0Á001). Treatments had no impact on EQ-5D-5L index scores. The number of comorbidities was associated with greater impairment in EQ-5D-5L index scores (P < 0Á001). The EQ-5D-5L index scores were significantly lower among patients with hypertension, musculoskeletal diseases, diabetes, thyroid disease and cardiovascular comorbidities (P < 0Á05).
Discussion
This is the first study to assess HRQoL in patients with pemphigus using the EQ-5D. Our results indicate that the EQ-5D-5L is a feasible and valid instrument for the evaluation of HRQoL for PV and PF. The EQ-5D-5L index scores correlated at least moderately with all other validated disease severity, pain and HRQoL measures, demonstrating good convergent validity of the instrument in patients with pemphigus. The literature is inconsistent with respect to the effect of sex and pemphigus subtype on HRQoL. In line with six other investigations, [26] [27] [28] [37] [38] [39] we observed no significant difference in HRQoL between women and men. Nevertheless, some authors found female patients with pemphigus to have significantly worse HRQoL. 40, 41 Regarding pemphigus subtypes, compared with PV, our patients with PF reported fewer problems in all five items of the EQ-5D-5L and had slightly better EQ-5D-5L index and EQ VAS scores. Nonetheless, this difference did not reach statistical significance. This corroborates findings from three earlier studies examining HRQoL in patients with PV and PF using the SF-36, DLQI and Skindex-29 questionnaires. 39, 40, 42 We also observed that patients with PV with mucocutaneous symptoms had the lowest EQ-5D-5L index scores, which highlights the importance of additional supportive treatments for patients with mucosal symptoms (e.g. topical corticosteroids, gels containing local anaesthetics and intralesional corticosteroid injections). 8, [43] [44] [45] Clinical severity, as evaluated by ABSIS, and EQ-5D-5L index scores correlated moderately. Interestingly, there was no significant correlation between the ABSIS and EQ VAS scores. The discrepancy in the convergent validity of EQ-5D-5L index scores and EQ VAS might be explained by the difference in how these two instruments capture health status. Not only the five dimensions of the EQ-5D descriptive system but also any aspects of HRQoL that matter to respondents may influence the way in which overall health is rated on the EQ VAS. 46 In fact, many patients indicating no problems at all in the five dimensions score themselves < 100 in the EQ VAS. 47 Skin erosions and ulcers in pemphigus may cause debilitating pain. To date, the damaging effects of pain on HRQoL in pemphigus have been demonstrated in a few studies. 39, 40, 48 One study from Iran found that the presence of pain did not have a significant negative effect on DLQI scores. 27 In contrast, our results suggest that pain intensity is one of the most important predictors of HRQoL in pemphigus. In clinical settings, thorough pain assessment using well-validated tools would be essential to develop personalized treatment plans for patients with pemphigus. 49 Providing effective pain relief has a pivotal role in improving patients' HRQoL. The patient-perceived impact of psoriasis is well known and widely studied in the literature. 50, 51 In accordance with previous studies in which the Short Form-36 and the World Health Organization Quality of Life-BREF were administered, 39, 40, 52 we found the impact of pemphigus to be very similar to that of psoriasis measured by the EQ-5D-5L. However, in contrast to psoriasis, pemphigus has a relatively high mortality rate, ranging from 5% to 30% after diagnosis depending on the length of follow-up. 53 The risk of death is approximately twoto threefold higher than in the general population. 2 Considering the high mortality rate, health benefits achieved with therapy are expected to be higher than with psoriasis, as effective treatments for pemphigus might improve both morbidity and mortality. This will also be reflected in the cost-effectiveness results of treatments that take into account both HRQoL improvement and life-years saved. It seems that pemphigus poses a large burden on patients when it comes to usual activities (e.g. working/studying, housework, family or leisure activities). The scientific evidence on productivity loss in patients with autoimmune blistering diseases is scarce. 54 In Canada, Heelan et al. reported a very large burden of autoimmune bullous diseases on ability to work using the Work Productivity and Activity ImpairmentSpecific Health Problem questionnaire. 55 More severe disease and larger HRQoL impairment were associated with greater productivity loss. Given the rarity of the disease, one of the greatest challenges in studying pemphigus is recruiting a sufficient number of patients. 56 In comparison with published clinical trials and HRQoL studies in the field, 12,57 the sample size of 109 patients with pemphigus may be considered relatively large. Further strengths of this study include the multicentre design, which allowed us to involve the four largest autoimmune bullous disease centres in Hungary, and the high rate of patients with PF, compared with other studies. 25, 28, 37, 39, 40, 52, 58, 59 To our knowledge, we were the first to obtain health utility values from patients with pemphigus. Up to now, only directly elicited utilities were available in pemphigus, generated with the time trade-off method from a general population sample. 13 Our findings are especially useful considering that in many countries such as the U.K., France, the Netherlands, Belgium, Hungary and Poland, national health technology appraisal bodies recommend the EQ-5D for measuring utilities. [60] [61] [62] [63] [64] [65] The following limitations should be noted. Firstly, patients with severe pemphigus were under-represented in the sample, which explains the rather good general health state of patients expressed by both the EQ-5D-5L and EQ VAS. Secondly, the English value set was applied in the study, because no national tariff is available for the EQ-5D-5L in Hungary. We acknowledge that there are several limitations of transferring value sets and EQ-5D scores across different jurisdictions. 66 Thirdly, in previous studies, the presence of antibodies against desmoglein 1 and 3 antigens was associated with disease activity and HRQoL in pemphigus. 39, 42, [67] [68] [69] Our study was a crosssectional questionnaire survey; no serum samples were collected from patients that could have allowed us to measure antidesmoglein antibody levels. In future studies, investigating the correlation between autoantibody levels and EQ-5D index scores is an important research direction. Finally, convergent validity was assessed against the ABSIS and DLQI. In validation studies, the Pemphigus Disease Area Index performed better than ABSIS in certain psychometric properties (e.g. intrarater variability, construct validity with desmoglein 1 and 3 autoantibodies). 33 Convergent validity could not been tested against autoimmune disease-specific HRQoL tools, such as the Autoimmune Bullous Disease Quality of Life (ABQOL) 70 and Treatment of Autoimmune Bullous Disease Quality of Life (TABQOL), 71 which were not available in Hungarian. The development of a mapping algorithm between ABQOL or TABQOL and EQ-5D index scores would be particularly beneficial in clinical trials where no health utilities are directly measured. These EQ-5D results in pemphigus are particularly timely. Since 2017, rituximab has been available as a first-line therapy for PV in the U.S.A., but in many other countries it is used only as a second-or third-line therapy for PV, in part owing to its high costs. 10 More patients with PV worldwide are expected to be treated with rituximab in the years to come. The EQ-5D allows measurement of the health gains associated with high-cost but very effective drugs, such as rituximab. No published cost-effectiveness analysis can be found in pemphigus; nevertheless, it is very likely that, similarly to psoriasis, 72 the EQ-5D will become the major tool to obtain HRQoL data in economic evaluations of pemphigus treatments. Thus, the EQ-5D scores reported in the present study support resource allocation decisions and might aid in improving patients' access to more effective medicines, in a condition for which only limited treatment options are currently available.
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